The Numbers Side by Side
Retatrutide Phase 2 (NEJM, 2023): −28.7% at 48 weeks at the 12mg dose cohort. Tirzepatide SURMOUNT-1: −22.5% at 72 weeks. Semaglutide STEP-1: −14.9% at 68 weeks.
The magnitude gap is not marginal — it is nearly 2× for Retatrutide vs Semaglutide. Understanding the mechanism explains why.
Three Receptors vs One
Semaglutide (GLP-1 S) is a selective GLP-1 receptor agonist. It binds GLP-1R and achieves its effects through: - Insulin secretion potentiation (pancreatic beta cells) - Appetite suppression (CNS GLP-1R: hypothalamus, brainstem) - Gastric emptying delay (enteric nervous system)
Tirzepatide adds GIPR agonism. GIP receptor co-activation potentiates insulin secretion beyond GLP-1 alone and may attenuate GLP-1-induced nausea at equivalent doses.
Retatrutide (GLP-3 R) adds glucagon receptor agonism on top of the dual GLP-1/GIP mechanism. This third receptor axis drives elevated energy expenditure through hepatic glucose production modulation and thermogenic pathway activation — effects neither GLP-1 nor GIP agonism achieves.
Why the Glucagon Axis Matters
Conventional concern with glucagon receptor agonism is hyperglycemia risk. The key insight in the Retatrutide mechanism is that GLP-1R co-activation suppresses glucagon-driven glycemic effects — the two axes balance. What remains is the energy expenditure benefit of glucagon signaling without the glycemic liability.
Research modeling suggests approximately 40% of Retatrutide's additional weight effect vs tirzepatide comes from the glucagon axis contribution to energy expenditure.
Timeline Adjustment
Note the timeline difference: Retatrutide data is at 48 weeks; semaglutide at 68 weeks. Adjusting for timeline, the gap narrows slightly but remains substantial. The dose also differs — Retatrutide 12mg vs Semaglutide 2.4mg (weight-management dose). Direct molecular comparison is not 1:1, but the Phase 2 signal is clear.
Research Implications
For research protocols exploring tri-receptor engagement vs mono-receptor baselines, Retatrutide represents the most data-rich compound in the class. Its Phase 2 profile established it as the strongest single-compound GLP signal in the current literature.